Clinical trial • Phase I • Neurology|Other
[11C]HSP990 for Alzheimer's disease|Amyotrophic lateral sclerosis|Parkinson's disease
Phase I trial of [11C]HSP990 for Alzheimer's disease|Amyotrophic lateral sclerosis|Parkinson's disease. 48 participants.
Overview
- Trial Therapeutic Area
- Neurology|Other
- Trial Disease
- Alzheimer's disease|Amyotrophic lateral sclerosis|Parkinson's disease
- Trial Stage
- Phase I
- Drug Modality
- Radiopharmaceutical
Key dates
- Initial CTIS Submission Date
- 30-04-2024
- First CTIS Authorization Date
- 13-06-2024
Trial design
Phase I trial across 1 site in Belgium.
- Target Sample Size
- 48
- Trial Duration For Participant
- 1262
Recruitment
- Planned Sample Size
- 48
- Recruitment Window Months
- 41
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 48
Belgium
- Earliest CTIS Part Ii Submission Date
- 27-05-2024
- Latest Decision Or Authorization Date
- 13-06-2024
- Processing Time Days
- 17
- Number Of Sites
- 1
- Number Of Participants
- 48
Sites
- Site Name
- UZ Leuven
- Department Name
- Nuclear Medicine and Molecular Imaging
- Principal Investigator Name
- Koen Van Laere
- Principal Investigator Email
- koen.vanlaere@kuleuven.be
- Contact Person Name
- Koen Van Laere
- Contact Person Email
- koen.vanlaere@kuleuven.be
- Number Of Participants
- 48
Sponsor
Primary sponsor
- Full Name
- UZ Leuven
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- [11C]HSP990
- Modality
- Radiopharmaceutical
Related trials
Other published trials that may interest you.
- PREDNISOLONE for Vestibular neuritis
- Ropivacaine hydrochloride for Lumbar fusion (lumbar arthrodesis)
- LIDOCAINE HYDROCHLORIDE for Spontaneous subarachnoid hemorrhage|Headache secondary to subarachnoid hemorrhage
- FLORTAUCIPIR (18F) for Alzheimer's disease|Alzheimer's pathology
- O15-WATER for Hydrocephalus|Communicating hydrocephalus|Non-communicating hydrocephalus